证券代码：002901 证券简称：大博医疗 公告编号：2023-041 具体内容详见公司于 2023 年 9 月 16 日刊登在指定信息披露媒体及巨潮 资讯网（www.cninfo.com.cn）上的《关于公司实际控制人及其一致行动人修改部 分自愿性承诺事项的公告》。 本议案需提交公司 2023 年第三次临时股东大会审议。 特此公告。 1 大博医疗科技股份有限公司 大博医疗科技股份有限公司 第三届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届监事会第五次会议于 2023 年 9 月 15 日在公司会议室以现场方式召开，会议通知以专人送达、传真、 电子邮件、电话相结合的方式已于 2023 年 9 月 1 日向各位监事发出，本次会 议应参加监事 3 名，实际参加监事 3 名，本次会议的召开符合《公司法》《公 司章程》等法律法规的规定，合法有效。 本次会议由监事会主席詹欢欢女士主持，与会监事就会议议案进行了审议、 表决，形成了如下决议： 一、会议以 3 票赞成、 0 票反对、 0 票弃权的 ...

证券代码：002901 证券简称：大博医疗 公告编号：2023-042 3、本次股东大会审议议案为特别决议事项，已由出席股东大会的股东（包 括股东代理人）所持表决权的 2/3 以上通过。 一、会议的召开和出席情况 大博医疗科技股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2023 年 9 月 15 日（星期五）下午 13:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2023 年 9 月 15 日上午 9:15 - 9:25、9:30 - 11:30，下午 13:00 - 15:00。 ①通过深圳证券交易所互联网投票系统投票的时间为 2023 年 9 月 15 日 上午 9:15 至下午 15:00 期间的任意时间。 2、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 1 3、 ...

关于持股 5%以上股东及其一致行动人持股比例变动 超过 1%的公告 证券代码：002901 证券简称：大博医疗 公告编号：2023-037 大博医疗科技股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 大博医疗科技股份有限公司（以下简称"公司"）于近日收到大博医疗国际 投资有限公司（以下简称"大博国际"）及其一致行动人赵少梅女士出具的《关 于持股比例变动超过 1%的告知函》，获悉大博国际及一致行动人所持公司的股 份比例变动超过 1%。根据《中华人民共和国证券法》《上市公司收购管理办法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规及规范性文件的规定，现将有 关情况公告如下： | 1．基本情况 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | | 大博国际、赵少梅 | | | | | | | | 住所 | | ROOM 3602, LEVEL 36, TOWER 1, ENTERPRI ...

Financial Performance - The company reported a total revenue of RMB 749,642,994.54, representing a year-on-year decrease of 9.47%[76]. - The net profit attributable to shareholders was RMB 93,535,390.85, down 48.08% year-on-year, while the net profit after deducting non-recurring gains and losses was RMB 64,791,096.29, a decline of 55.09%[76]. - Cash flow from operating activities was negative at RMB -57,073,523.67, a significant decrease of 705.44% year-on-year[76]. - The company reported a revenue of 500 million yuan for the first half of 2023, representing a 20% increase year-over-year[193]. - The company expects a revenue growth forecast of 25% for the second half of 2023, driven by new product launches[193]. Product Development and R&D - The main business of the company remains the production, research and development, and sales of high-value medical consumables, with no significant changes in major products during the reporting period[15]. - The company is actively involved in the research and development of new medical technologies and products to enhance its market position[37]. - Research and development expenses rose by 22.75% to ¥125,550,165.56, driven by an increase in R&D personnel and direct investment in R&D[123]. - The company has established a comprehensive R&D system with a team of experienced professionals in the orthopedic field[144]. - The company has introduced two new medical devices, projected to generate an additional 100 million yuan in revenue by Q4 2023[193]. Market and Sales Strategy - The company has established a sales network covering over 30 provinces and cities in China, enhancing its competitive advantage in the market[118]. - The company exports products to over 60 countries, including Australia, Russia, and Ukraine, which has improved its brand reputation and market influence overseas[118]. - The company is focusing on expanding its product line in high-value medical consumables, including hip joint prostheses and spinal fusion devices, to maintain its competitive edge[119]. - The company is focusing on international market expansion, with products sold in over 60 countries and regions[141]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[193]. Financial Management and Investments - The company plans not to distribute cash dividends or issue bonus shares for the current period[4]. - The company has invested RMB 2,932.15 million in the orthopedic implant consumables production line expansion project, achieving 95.83% of the planned investment[94]. - The company plans to invest raised funds in expanding orthopedic implant consumables production lines and constructing oral implant production lines, as well as supplementing working capital[179]. - The company acknowledges the uncertainty regarding the successful completion and expected benefits of the fundraising investment projects due to potential changes in market conditions and macroeconomic factors[179]. Compliance and Governance - The company emphasizes the importance of compliance with international standards such as CE and FDA for its products[24]. - The company has established a good communication platform with investors through various channels to enhance transparency and credibility[190]. - The company emphasizes compliance with securities regulatory laws and regulations regarding related party transactions, ensuring fair and reasonable pricing[175]. - The company has disclosed that there are no undisclosed related party transactions during the reporting period[175]. Operational Efficiency - The company has established a procurement model based on annual sales forecasts to optimize its supply chain[38]. - The company has established a comprehensive procurement management system to ensure the quality of purchased materials, requiring suppliers to provide necessary certifications and quality assurance[67]. - The company has implemented a regional management and distributor authorization model to maintain market stability and compliance, evaluating distributors based on their qualifications and performance[44]. - The company has established a three-day rolling plan for major production workshops to optimize production efficiency[42]. Social Responsibility and Community Engagement - The company is committed to fulfilling its social responsibilities and enhancing shareholder value through sustainable development practices[162]. - The company has a commitment to social responsibility, actively participating in charitable activities and contributing to local economic development[190]. - The company is actively engaged in public relations and social welfare initiatives to enhance its corporate image and community relations[166]. Challenges and Risks - The company faces exchange rate risks as some raw material purchases and overseas sales are settled in USD, which could impact purchasing power and lead to potential foreign exchange losses[150]. - The company is adapting its strategies in response to national healthcare reforms and pricing policies affecting high-value medical consumables[130].

本次变更不影响中信证券对公司的持续督导工作。本次变更后，公司首次公 开发行股票项目持续督导的保荐代表人为丁元女士、赵陆胤女士。 公司董事会对罗耸先生在担任公司保荐代表人期间所做的工作表示衷心的 感谢！ 特此公告。 附件：赵陆胤女士简历 证券代码：002901 证券简称：大博医疗 公告编号：2023-028 大博医疗科技股份有限公司 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）于近日收到保荐机构中信 证券股份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》， 中信证券作为公司 2020 年度非公开发行股票的保荐机构，委派丁元女士、罗耸 先生担任公司非公开发行股票后持续督导的保荐代表人，法定持续督导期限至 2023 年 12 月 31 日。 现保荐代表人罗耸先生因工作变动原因，不能继续担任公司持续督导的保荐 代表人。为保证持续督导工作的有序开展，中信证券现委派保荐代表人赵陆胤女 士（简历见附件）接替罗耸先生继续履行公司首次公开发行股票项目后续的持续 督导工作，继续履行持续督导 ...

Financial Performance - The total operating revenue for the first quarter was approximately CNY 431.07 million, with a net profit attributable to shareholders of CNY 111.53 million[32]. - In the second quarter, the operating revenue decreased to approximately CNY 396.95 million, while the net profit attributable to shareholders was CNY 68.37 million[32]. - The third quarter saw a slight increase in operating revenue to approximately CNY 406.84 million, but the net profit attributable to shareholders dropped to CNY 32.48 million[32]. - The fourth quarter reported a significant decline in operating revenue to approximately CNY 199.24 million, resulting in a net loss attributable to shareholders of CNY -120.16 million[32]. - The company's operating revenue for 2022 was ¥1,434,099,180.05, a decrease of 28.09% compared to ¥1,994,333,825.91 in 2021[52]. - The net profit attributable to shareholders for 2022 was ¥92,218,972.93, down 86.30% from ¥673,309,413.17 in the previous year[52]. - The basic earnings per share for 2022 was ¥0.22, a decline of 86.90% compared to ¥1.68 in 2021[52]. - The gross profit margin for the medical device manufacturing sector was 76.72%, down 7.69% from the previous year[102]. - Trauma products revenue dropped by 51.89% to ¥542,453,667.00, accounting for 37.83% of total revenue[102]. - The revenue from spinal products decreased by 16.50% to ¥472,100,781.95, representing 32.92% of total revenue[102]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -110.52 million in the first quarter, but improved to CNY 119.95 million in the second quarter[32]. - The company reported a significant decrease in cash flow from operating activities, with a net cash flow of ¥128,444,750.90 in 2021 compared to a loss in 2022[52]. - The total cash flow from financing activities was CNY 799,200,000.00, with a net cash flow of CNY 246,810,659.80, compared to a net outflow of CNY -228,312,218.73 in the previous period[131]. - The company's cash and cash equivalents increased by CNY 78,602,714.31, ending the period with CNY 98,590,484.30, compared to CNY 19,987,769.99 at the beginning of the period[131]. - The total investment amount for the reporting period was CNY 88,371,363.01, a decrease of 36.94% compared to CNY 140,149,359.80 in the same period last year[119]. Market and Industry Trends - The orthopedic medical device industry is experiencing steady growth due to increasing demand from the aging population and rising incidence of orthopedic diseases[36]. - The orthopedic medical device industry in China is experiencing significant growth, driven by increasing demand for healthcare and government support for domestic production[62]. - The average price reduction for orthopedic trauma medical consumables in the Beijing-Tianjin-Hebei region reached 83.48% following a new round of centralized procurement[88]. - The domestic orthopedic medical device market is expected to continue expanding, with a focus on local production and innovation due to supportive national policies[62]. - The ongoing trend of domestic substitution in the orthopedic medical device market is expected to accelerate, providing substantial growth opportunities[62]. Company Strategy and Operations - The company plans to focus on expanding its market presence and enhancing its product offerings in response to favorable national policies and market demand[36]. - The company plans to continue focusing on the production and sales of high-value medical consumables, with no major changes in its main business operations reported[41]. - The company plans to expand its product lines in minimally invasive surgery, neurosurgery, and dental high-value consumables to drive long-term growth[91]. - The company aims to enhance production and operational efficiency to reduce costs and improve profit margins post-price reductions from centralized procurement[91]. - The company plans to strengthen its advantages in trauma and spinal orthopedic consumables, expanding production capacity to meet future demand and increase market share[183]. - The company aims to accelerate the production of innovative artificial joint prosthetics, targeting the fastest-growing segment in the domestic orthopedic implant market[183]. Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, with all board members present for the review[3]. - The company has a governance structure that complies with relevant laws and regulations, ensuring independent financial decision-making and operations[188][193]. - The company has a board of directors consisting of 7 members, including 3 independent directors, ensuring compliance with governance standards[188]. - The management has outlined potential risks and corresponding strategies in the report, emphasizing the importance of risk awareness for investors[4]. Subsidiaries and Human Resources - The subsidiary Bo Yi Ning (Xiamen) Medical Equipment Co., Ltd. reported total assets of CNY 229,617,756.40 and net profit of CNY 6,536,047.21[156]. - The subsidiary Shi Ai De (Xiamen) Medical Equipment Co., Ltd. achieved total revenue of CNY 195,046,067.81 and net profit of CNY 39,149,377.90[156]. - The subsidiary Shenzhen World Surgical Medical Technology Co., Ltd. reported total revenue of CNY 59,301,238.50 and net profit of CNY 12,789,968.56[156]. - The company plans to continue implementing a human resources strategy focused on talent acquisition in marketing, academic promotion, R&D, production, and management to support rapid growth[161]. - The company is committed to enhancing its workforce's skills through various training opportunities, promoting employee development and satisfaction[190].

大博医疗科技股份有限公司 2023 年第一季度报告 大博医疗科技股份有限公司 重要内容提示： 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 1 一、主要财务数据 证券代码：002901 证券简称：大博医疗 公告编号：2023-016 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3.第一季度报告是否经过审计 大博医疗科技股份有限公司 2023 年第一季度报告 2023 年第一季度报告 □ 是 √ 否 公司是否需追溯调整或重述以前年度会计数据 （二）非经常性损益项目和金额 2 单位：元 合计 □ 适用 √ 不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 □ 适用 √ 不适用 公司不存在将《公开发行证券的公 ...

Revenue and Profit - Revenue for Q3 2022 was CNY 406,836,403.52, a decrease of 11.23% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 32,484,227.54, down 76.17% year-on-year[4] - Net profit excluding non-recurring items was CNY 80,908,714.97, a decline of 36.17% compared to the previous year[4] - Basic earnings per share were CNY 0.0785, a decrease of 76.90% year-on-year[5] - Net profit for Q3 2022 was CNY 225,408,848.04, down from CNY 471,584,415.37 in the same period last year, reflecting a decrease of approximately 52.3%[48] - The total comprehensive income for the period amounted to CNY 222,618,155.71, a decrease from CNY 471,170,415.39 in the previous period[52] - The basic and diluted earnings per share were both CNY 0.5170, down from CNY 1.1314 in the same period last year[52] Cash Flow and Liquidity - Operating cash flow for the year-to-date was CNY 37,453,143.64, down 88.70%[5] - The net cash flow from operating activities was CNY 37,453,143.64, significantly lower than CNY 331,365,409.19 in the prior period[55] - The cash inflow from investment activities decreased to CNY 4,149,993,532.30 from CNY 5,139,460,716.53 year-over-year[55] - The net cash flow from financing activities was CNY 255,531,146.74, recovering from a negative CNY 273,643,758.09 in the previous period[56] - The company reported a total cash and cash equivalents balance of CNY 124,913,634.11 at the end of the period, up from CNY 18,042,041.52 at the end of the previous period[56] - The cash outflow for operating activities totaled CNY 1,416,856,874.94, compared to CNY 1,087,318,626.93 in the prior year[55] - The company received CNY 490,156,165.30 from investment activities, a significant increase from CNY 79,340,576.00 in the previous period[56] - The company's cash and cash equivalents were not explicitly mentioned, but the overall financial position indicates a focus on managing liquidity amid rising costs[46] Assets and Liabilities - Total assets increased to CNY 3,947,644,819.44, up 16.80% from the end of the previous year[5] - Total current assets reached ¥2,791,025,804.51, compared to ¥2,395,093,034.31 at the beginning of the year[16] - Total liabilities decreased to CNY 728,015,726.96 from CNY 791,470,911.11, a reduction of about 8%[29] - The total equity attributable to shareholders increased to CNY 3,120,067,614.08 from CNY 2,512,476,209.50, reflecting a growth of about 24.1%[42] Expenses and Costs - Total operating costs increased significantly to CNY 1,045,177,711.08 from CNY 807,468,943.74, marking an increase of about 29.4%[46] - Management expenses increased by 51.86% to ¥93,883,198.30 due to personnel increases and accelerated stock option expenses[10] - R&D expenses rose by 70.56% to ¥186,012,065.32, attributed to an increase in R&D personnel and direct investments[10] - The company reported a significant increase in sales expenses, which amounted to CNY 527,424,951.21, compared to CNY 439,900,625.01 in the previous year, an increase of approximately 19.9%[48] Strategic Initiatives - The company plans to adjust its business strategy to enhance market share following successful bids in national and provincial centralized procurement for orthopedic products[5] - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by the increase in R&D spending and overall investment in growth strategies[48] Other Financial Metrics - Financial income improved by 148.63%, reaching -¥19,845,943.79, mainly due to increased interest from deposits and foreign exchange gains[10] - Other income increased by 59.06% to ¥63,529,160.31, primarily from government subsidies received[10] - Fair value changes resulted in a gain of ¥5,550,922.14, a significant increase of 2712.57% compared to the previous period[10] - Credit impairment losses decreased by 113.72% to ¥613,605.50, due to a reduction in long-aged accounts receivable[10] - The total number of ordinary shareholders at the end of the reporting period was 29,707, with the largest shareholder holding 43.13%[11] - Cash and cash equivalents rose to CNY 644,567,891.25, a 57.14% increase attributed to funds received from a private placement[9] - Inventory rose to ¥896,678,881.36, up from ¥670,151,967.35 at the start of the year[16] - The company reported a significant increase in inventory, reaching CNY 896,678,881.36, up 33.80% due to increased procurement demand[9]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥828,018,203.47, a decrease of 2.19% compared to the same period last year[23]. - The net profit attributable to shareholders was ¥179,894,580.26, down 43.28% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥144,022,265.63, representing a 49.17% decline compared to the previous year[23]. - The net cash flow from operating activities was ¥9,426,858.66, a significant drop of 95.88% from the same period last year[23]. - Basic earnings per share decreased by 44.23% to ¥0.4371[23]. - The overall gross margin for the reporting period was 80.97%[62]. - The company experienced a 3.66% decline in gross margin for orthopedic trauma products due to centralized procurement, leading to a 23.18% decrease in revenue for these products[61]. - Revenue for orthopedic spine products increased by 23.83%, while orthopedic joint products and minimally invasive surgical products saw revenue growth of 216.29% and 56.82%, respectively[61]. - The company's operating costs rose by 30.15% to ¥157,533,129.86, attributed to the effects of centralized procurement policies[76]. - Sales expenses increased by 21.19% to ¥335,279,409.56, driven by higher personnel salaries and promotional service fees, as well as increased stock incentive costs[76]. - Management expenses surged by 43.49% to ¥54,525,355.49, mainly due to an increase in personnel leading to higher employee compensation and stock incentive costs[76]. Assets and Investments - Total assets at the end of the reporting period were ¥3,863,250,788.39, an increase of 14.30% from the end of the previous year[23]. - The net assets attributable to shareholders increased by 19.74% to ¥3,008,410,939.90[23]. - The total investment amount for the reporting period was ¥70,601,631.15, representing a 224.30% increase compared to ¥21,770,311.41 in the same period last year[90]. - The company has raised a total of ¥48,721.7 million through private placement, with ¥31,278.49 million already utilized, leaving ¥17,568.58 million unutilized[97]. - The company has pre-invested CNY 14,033.68 million in fundraising projects, with CNY 12,859.45 million allocated to the orthopedic implant consumables production line expansion project[100]. Research and Development - Research and development investment in the first half of the year amounted to ¥102,284,125.47, an increase of 53.52% year-on-year, indicating a strong commitment to innovation and new product lines[63]. - The company holds 494 patents, including 53 invention patents, 359 utility model patents, and 82 design patents, showcasing its strong R&D capabilities[67]. - The company is focusing on expanding its product lines in orthopedic implants, including hip joint prostheses and spinal fusion devices, to strengthen its market position[73]. - The company is committed to increasing R&D investment to align with industry development trends and ensure sustainable growth[111]. Market and Operations - The main business of the company involves the production, research and development, and sales of high-value medical consumables, with no significant changes reported during the period[33]. - The company has established a comprehensive marketing network across all regions in mainland China and some overseas areas, supported by over 600 sales personnel[58]. - The company continues to focus on expanding its market presence and developing new products in the medical consumables sector[44]. - The company is well-positioned to benefit from the shift of medical resources towards secondary hospitals, which are becoming increasingly important in the high-value consumables market[74]. - The company has achieved a significant presence in tertiary hospitals, enhancing its brand recognition and competitiveness against multinational companies in the high-value consumables sector[74]. Risks and Challenges - The company faces risks from high-value orthopedic consumables procurement policies, which may lead to price reductions affecting future performance[106]. - The company is also at risk from potential sales declines due to the ongoing COVID-19 pandemic and its impact on domestic and international markets[107]. - The company is closely monitoring industry policy changes that could affect the pricing and distribution of high-value consumables[108]. - The company faces high research and development costs and long product registration times for orthopedic consumables, which may impact future profitability if new products do not meet market demands[111]. Corporate Governance and Commitments - The company emphasizes the importance of intellectual property rights, as they are crucial for maintaining competitive advantage in a highly competitive orthopedic medical device market[112]. - The company has established a mechanism to ensure the fulfillment of public commitments made during its initial public offering[148]. - The company has committed to maintaining transparency in related party transactions and ensuring fair pricing based on market standards[150]. - The company has pledged to compensate investors for any direct losses incurred due to unfulfilled commitments, with measures including using its own funds for compensation[150]. - The company emphasizes the protection of shareholder and creditor rights by adhering to relevant laws and regulations, ensuring timely and accurate disclosure of significant events[135]. Shareholder Information - The largest shareholder, Changdu Dabotong Medical Investment Management Co., Ltd., holds 43.13% of the total shares, amounting to 179,928,000 shares[194]. - The second-largest shareholder, Dabotong Medical International Investment Co., Ltd., owns 22.07% of the shares, totaling 92,064,290 shares[194]. - The third-largest shareholder, Lin Zhijun, holds 19.37% with 80,807,710 shares, of which 20,201,928 shares are unrestricted[194]. - The total number of common shareholders at the end of the reporting period is 25,901[194]. - The report indicates that there are no changes in the voting rights of the shareholders[197].

Financial Performance - The company's revenue for Q1 2022 was CNY 431,071,714.35, representing a 14.94% increase compared to CNY 375,030,218.30 in the same period last year[6] - Net profit attributable to shareholders decreased by 14.58% to CNY 111,527,418.23 from CNY 130,569,345.57 year-on-year[6] - Total operating revenue for the first quarter was 431,071,714.35, an increase from 375,030,218.30 in the previous year, representing a growth of approximately 15%[22] - Net profit for the first quarter was 114,474,304.94, down from 134,814,713.36, indicating a decrease of approximately 15%[24] - The company achieved a total comprehensive income of 115,115,756.41, down from 135,090,185.91, indicating a decrease of about 15%[27] - Basic earnings per share decreased to 0.27 from 0.33, a decline of approximately 18%[27] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -110,519,784.68, a decline of 309.62% compared to CNY 52,724,072.25 in the previous year[6] - The company reported a net cash outflow from operating activities of -110,519,784.68, compared to a positive cash inflow of 52,724,072.25 in the previous year[29] - The net cash flow from investment activities was -64,805,198.44 CNY, compared to -77,983,483.96 CNY in the previous period, indicating an improvement[31] - The total cash inflow from financing activities was 488,320,000.00 CNY, while the cash outflow was 2,340,614.57 CNY, resulting in a net cash flow of 485,979,385.43 CNY[31] - The net increase in cash and cash equivalents for the quarter was 310,799,583.82 CNY, contrasting with a decrease of 24,950,777.27 CNY in the previous period[31] - The ending balance of cash and cash equivalents was 372,551,453.52 CNY, up from 23,188,152.58 CNY in the previous period[31] - The cash inflow from investment activities totaled 1,251,735,262.06 CNY, while cash outflow was 1,316,540,460.50 CNY, leading to a net cash flow from investment activities of -64,805,198.44 CNY[31] Assets and Liabilities - Total assets increased by 13.74% to CNY 3,844,343,059.44 from CNY 3,379,858,314.48 at the end of the previous year[6] - Current liabilities decreased to ¥575,274,039.45 from ¥721,780,002.69, a reduction of approximately 20.3%[19] - The total liabilities decreased to 640,299,589.92 from 791,470,911.11, a reduction of approximately 19%[22] - The company's equity attributable to shareholders rose by 24.37% to CNY 3,124,699,338.95 from CNY 2,512,476,209.50[6] - The equity attributable to shareholders increased to 3,124,699,338.95 from 2,512,476,209.50, reflecting a growth of about 24%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 26,234[10] - The largest shareholder, Changdu Dabotong Medical Investment Management Co., Ltd., holds 43.13% of the shares, totaling 179,928,000 shares[10] - The top ten shareholders include significant stakes from both domestic and foreign entities, with the largest foreign shareholder holding 22.07%[14] Research and Development - Research and development expenses increased by 51.92% to CNY 47,245,795.19 from CNY 31,098,383.66 year-on-year[8] - Research and development expenses rose to 47,245,795.19 from 31,098,383.66, marking an increase of about 52%[24] Government Support and Market Conditions - The company received government subsidies amounting to CNY 9,091,685.84, a 119.35% increase from CNY 4,144,922.30 in the previous year[9] - The fair value changes of financial assets resulted in a gain of CNY 4,503,165.72, a significant increase of 2039.38% compared to a loss of CNY -232,196.67 in the previous year[9] - The company is facing challenges due to the implementation of bulk purchasing results and the impact of recurring COVID-19 outbreaks on its operational performance[17] - The company is actively exploring new strategies and market expansions in response to competitive pressures in the medical supplies sector[17] Operational Costs - Total operating costs increased to 313,846,809.66 from 222,749,392.94, reflecting a rise of about 41%[22] - Cash received from sales of goods and services was 395,785,137.20, a decrease from 408,213,543.76 in the previous year[29] Audit Information - The company did not conduct an audit for the first quarter report[32]